Overall, it is not possible to draw definite conclusions on the s

Overall, it is not possible to draw definite conclusions on the safety and tolerability of neuroprotective agents from the studies conducted so far especially in chronic applications as required in glaucoma management. We are of the opinion that click here clinical viability of neuroprotective agents in glaucoma will require drug delivery systems that can achieve intraocular bioavailability

Inhibitors,research,lifescience,medical while maintaining therapeutic drug levels at minimal dosing times. 2.2. Overview of Implantable Delivery Systems for Antiglaucoma Therapeutics Ideal qualities for glaucoma drug delivery systems include the following: sustained delivery of drug (therapeutics) to the desired segment of the eye, ability to tailor drug delivery to the natural progression of the disease, achieve high ocular drug bioavailability, improve local drug activity while allaying concerns of systemic side effects or complications at the site of administration, drug Inhibitors,research,lifescience,medical administration should be noninvasive or minimally invasive without interfering with vision, drug delivery platforms should be safe and nontoxic while ensuring patient acceptance. Implantable delivery systems can potentially surmount the challenge of patient nonadherence to therapy while offering localized controlled drug delivery. There are a

Inhibitors,research,lifescience,medical diverse range of biocompatible implantable devices which include nondegradable and biodegradable drug pellets, bioerodible scleral plugs, films and discs, and polymeric matrices in different shapes and sizes that aid delivery of drugs to the Inhibitors,research,lifescience,medical posterior eye segment [28, 29]. These are considered as alternatives to repeated intravitreal injections with the ability to modulate

drug release and extend intraocular half-life of therapeutics [30, 31]. Examples of sustained release implants in some preclinical glaucoma models are summarized in Table 1. Although there are a number of implantable delivery systems that are being studied in glaucoma management, none of the implants/formulations is currently FDA approved or marketed for treatment of this disease. Majority of the research work in this area Inhibitors,research,lifescience,medical have only been done in preclinical Histone demethylase models. Examples of sustained release drug delivery systems specifically designed for glaucoma that are undergoing clinical development are listed in Table 2. Perhaps it would take several years before a viable sustained release delivery system (implantable device) will become commercially available with acceptable safety risk profiles. Table 1 Examples of sustained release delivery systems studied in glaucoma-induced preclinical models. Table 2 Examples of sustained release delivery systems for glaucoma that are under clinical development. 2.2.1. Biodegradable Ocular Implants The key feature of implantable delivery systems that are fabricated from biodegradable polymers is that they do not require postapplication removal of implants after successfully delivering the loaded drugs/therapeutic agents.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>